作者@article {Lacomblez242S = {L。Lacomblez g . Bensimon和p . n .利p Guillet l·鲍威和美国Durrleman j . c . Delumeau诉专职阿訇},title ={确认dose-ranging研究利鲁唑在ALS},体积={47}={6 5 4},页面={242年代——250年代}= {1996},doi = {10.1212 / WNL.47.6_Suppl_4.242S},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘= {ALS是一种进步的运动神经元疾病,没有有效的治疗方法。首页专业药物利鲁唑(100毫克/天)已被证明会降低死亡率和ALS患者的肌肉退化。确认和扩展利鲁唑的治疗效果,我们进行了双盲、安慰剂对照、多中心、国际dose-ranging(100, 200毫克/天),959年的分层研究肌萎缩性侧索硬化症门诊治疗长达18个月。主要功效标准是生存和治疗的效果进行了分析(Wilcoxon和日志等级测试)和前调整后预后因素(Cox模型)。次要疗效标准是通过改变疾病进展评估功能的措施。Tracheostomy-free存活率是:50.4 \ %(安慰剂),55.3 \ %(50毫克利鲁唑)(p = 0.23, Wilcoxon测试;生存率较p = 0.25), 56.8 \ %(100毫克利鲁唑)(p = 0.05, Wilcoxon测试;生存率较p = 0.076),和57.8 \ %(200毫克利鲁唑)(p = 0.061, Wilcoxon测试;生存率较,p = 0.075)。在18个月的研究结束时,有一个显著的剂量相关的死亡风险下降或气管造口术(p = 0.04)。 Adjustment for baseline prognostic factors showed a 35\% decreased risk of death with the 100-mg dose compared with placebo (p = 0.002). No significant treatment effects were detected for the functional assessments. The most frequent dose-related adverse events included nausea, asthenia, and elevated liver enzyme levels. This study confirms the therapeutic effect of riluzole in a large representative ALS sample, over an 18-month period. Riluzole is well tolerated and decreases the risk of death or tracheostomy in ALS patients. NEUROLOGY 1996;47(Suppl 4): S242-S250}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/47/6_Suppl_4/242S}, eprint = {//www.ez-admanager.com/content/47/6_Suppl_4/242S.full.pdf}, journal = {Neurology} }